Balyasny Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Balyasny Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,147	Closed	-$347K	–	2944
2022 Q3	$347K	Buy	+8,147	New	+$417K	﹤0.01%	2147
2021 Q3	–	Sell	-18,020	Closed	-$1.24M	–	2115
2021 Q2	$1.24M	Sell	18,020 -50,109	-74%	-$3.82M	0.01%	1185
2021 Q1	$5.25M	Buy	68,129 +54,957	+417%	+$5.06M	0.03%	682
2020 Q4	$1.3M	Buy	+13,172	New	+$1.61M	0.01%	964

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Balyasny Asset Management's LKFT Position: Q4 2022 in Review

Balyasny Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 8,147 shares — an estimated $347K sold.

Balyasny Asset Management first reported a position in LKFT in Q4 2020 and held it in 4 quarters. The position peaked at $5.25M in Q1 2021. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

Balyasny Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Balyasny Asset Management sold 8,147 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $347K.
Balyasny Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 4 quarters.
Balyasny Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.25M in Q1 2021.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.